1 / 9

Polycystic Kidney Disease Global Clinical Trials Review, H1, 2018

Polycystic kidney disease is a genetic kidney disease which means that it is cause by a problem with the abnormal genes which produce a specific abnormal protein which has an adverse effect on tubule development.

kenresearch23
Télécharger la présentation

Polycystic Kidney Disease Global Clinical Trials Review, H1, 2018

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Growing Landscape Of The Global Clinical Trials For The Polycystic Kidney Disease Market Outlook: Ken Research

  2. SUMMARY • Global Data's clinical trial report, Polycystic Kidney Disease Global Clinical Trials Review, H1, 2018 provides an overview of Polycystic Kidney Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Polycystic Kidney Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). • The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. • *Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

  3. POLYCYSTIC KIDNEY DISEASE • According to the report analysis, ‘Polycystic Kidney Disease Global Clinical Trials Review, H1, 2018’ some of the major companies and healthcare organizations which are operating in this market with more efficiency includes otsuka holdings co ltd, pfizerinc,ipsensakadmoncorpllc, novartisag, merck & co inc, iqvia holdings inc, davita inc, daiichisankyo co ltd, c. H. Boehringersohnag & co kg, glaxosmithkline, sanofi, elililly and company, johnson & johnson, bristol-myerssquibb company, abbottlaboratries, hoffmann-la roche ltd., celegene corporation, bayerag, eisai inc. • European organization for research and treatment of cancer, dana-farber cancer institute, case comprehensive cancer center, mayo clinic, duke university, ohio state university, university of pennsylvania and others. Moreover, for the better treatment of polycystic kidney disease more and more laboratories are established with more advance instrument for performing tests, related to the treatment of this disease.

  4. POLYCYSTIC KIDNEY DISEASE • Polycystic kidney disease is a genetic kidney disease which means that it is cause by a problem with the abnormal genes which produce a specific abnormal protein which has an adverse effect on tubule development. Polycystic kidney disease which is also known as polycystic kidney syndrome. • Polycystic kidney disease causes cysts to produce inside the kidneys whereas, these cysts make the kidneys much bigger than that of their normal size and can damage the tissue. Moreover, polycystic kidney disease is a of chronic kidney disease that decrease the functions of kidney and may result to kidney failure or end-stage renal disease. • Additionally, with more advancement in the technology, upgradation in the old processing unit and establishment of new healthcare organization will lead to the significant growth in the coming years with more efficiency in the treatment.

  5. POLYCYSTIC KIDNEY DISEASE • Geographically, the with high prevalence of the disease the market has been spread across the globe which majorly includes Asia-pacific region, Europe, North America, middle east and Africa, central and south America. Moreover the symptoms of polycystic kidney disease symptoms includes high blood pressure, back or side pain, headache, blood in urine, kidney failure and frequent urination. • As the symptoms are more critical, the treatment or prevention which includes antihypertensive drugs and diuretics of this disease results to significant growth. In addition, increase in the research and development, high prevalence of disease, growing more opportunities from the funding of the new entrants are driving the growth in the vaccines market. • Therefore, with the new entrants of the key players in the market it is expected that in future, the market will grow more significantly in the coming years.

  6. Browse Full Market Report • Polycystic Kidney Disease Global Clinical Trials Review, H1, 2018 • Related reports: • Polycystic Kidney Disease-Pipeline Review, H1 2017 • Polycystic Kidney Disease Global Clinical Trials Review, H2, 2016

  7. About ken research • Ken Research provides bespoke industry intelligence, equity research reports and business consulting services on gamut of sectors across the globe. We use advanced information management tools, sophisticated analytical systems and methodologies to help our clients with crucial industry information for decision making. • As a leading Online Market Research Report Seller, Ken Research act as a platform for accessing statistics, forecast, business insights, Ideas, concepts and much more.

  8. Contact Us: • Ken Research • Ankur Gupta, Head Marketing & Communications • sales@kenresearch.com • +91-9015378249

More Related